Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy. The accelerated approval was ...

A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and ...

40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review[2]; primary efficacy endpoint requires ...

Patients with advanced synovial sarcoma may have a new therapy option if the novel drug, afami-cel, is approved by the FDA after the priority review. The Food and Drug Administration (FDA) has ...

Natasha Allen was a rising TikTok creator who shared her journey with synovial sarcoma, a rare and aggressive form of cancer. Over the years, she built a community of nearly 200,000 followers by ...

At 16, Eldiara Doucette felt pain in her right arm that she struggled to describe. “It could have easily been classified with a standard teenage ‘growing pains,’ which is, unfortunately, how a lot of ...

A PDUFA target date of August 4, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to afamitresgene autoleucel for certain adults with unresectable or ...

Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...

Megan, a 26-year-old synovial sarcoma survivor, joins Marc to share her personal story and challenging diagnosis journey Dr. John Charlson, oncologist and sarcoma specialist, to discuss the importance ...

Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan University-led research team has found. The group irradiated ...

Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma ...